Magle Chemoswed Holding
9.00 SEK
+11.11 %
Less than 1K followers
MAGLE
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
+11.11 %
-44.10 %
-48.86 %
-50.28 %
-58.72 %
-73.99 %
-65.25 %
-77.10 %
-55.21 %
The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes three operational areas. Magle Chemoswed, a contract development and manufacturing organization (CDMO). Magle PharmaCept, an established sales and marketing company for the development and direct sales of the Groups medical technology products, and Magle Biopolymers A/S, a specialized manufacturing organization of Dextran technology.
Read moreMarket cap
185.84M SEK
Turnover
121.08K SEK
Revenue
236.04M
EBIT %
9.84 %
P/E
0.21
Dividend yield-%
-
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
27.3
2026
Annual report '25
18.5
2026
Interim report Q1'26
26.5
2026
General meeting '26
All
Press releases
3rd party
ShowingAll content types
Magle Group Announces Strategic Refocus to Strengthen Profitability and Operational Discipline
Magle Group Announces Planned Transition in Chief Operating Officer Role
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools